CHARACTERISTICS OF THE IDEAL DCB

- Must deliver the drug to the arterial wall during inflation
  - Drug must distribute evenly within the intima/media in the first few days
- Therapeutic drug levels must be maintained for more than 28- days
  - Biologic effects must be observed by histology at 28-days in animal models
- Non-target effects should be minimized

COMPARISON TO BENCHMARK DCBS

<table>
<thead>
<tr>
<th>DCB #1</th>
<th>DCB #2</th>
<th>DCB #3</th>
</tr>
</thead>
<tbody>
<tr>
<td>SurVeil® DCB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaft coating</td>
<td>Serene® Hydrophilic coating</td>
<td></td>
</tr>
<tr>
<td>Uniform Drug Topcoat</td>
<td>Pecribio® proprietary excipient</td>
<td></td>
</tr>
<tr>
<td>2.0 µg/mm² drug load</td>
<td></td>
<td></td>
</tr>
<tr>
<td>360° coating coverage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.035” OTW PTA platform</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caution: Investigational device</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**EFFICIENT DRUG DELIVERY: TISSUE CONCENTRATION OVER 28 DAYS**

![Graph showing tissue concentration over 28 days with data points for different groups.](image)

Results in the swine model. All data from Surmodics-sponsored studies.

**UNIFORM ROBUST BIOLOGICAL DRUG EFFECT AT 28 DAYS**

![Graph comparing drug effect at 28 days.](image)

Results in the swine model. All data from Surmodics-sponsored studies.

**VISIBLE DIFFERENCES IN COATING INTEGRITY (SUBMERGE AND DEPLOY TESTING)**

- **Benchmark DCB #1**
- **Benchmark DCB #2**
- **Surmodics SurVeil DCB**

Visible Difference in Particulates Released Upon Inflation

**TRACK AND DEPLOY PARTICULATE**

**Method summary**
- Simulated device use
  - Prepare balloon
  - Track through guide catheter in an anatomical model (Isoton, 37°C)
  - Inflate to 14 atm (RBP) in mock vessel, dwell for 30s
  - Deflate, withdraw balloon from model
  - Flush model to recover particulates
- Measurements:
  - Particulate counts
  - Drug retained on balloon
  - Drug recovered from mock vessel

**DCB COMPARISON: PARTICULATE FROM SIMULATED USE**

Different paper showing differences following track and deploy testing

**DOWNSTREAM TISSUE CONCENTRATION-MINIMIZING NON-TARGET EFFECTS**

![Graph showing downstream tissue concentration.](image)

Results in the swine model. All data from Surmodics-sponsored study.
CONCLUSION

- Currently available DCBs have downstream emboli in preclinical models
- SurVeil DCB with advanced coating technology and a lower drug dose is able to achieve effective drug transfer into the arterial wall while minimizing downstream embolic effects in preclinical models